Short-term antiretroviral therapy fails to reduce the expanded activated CCR5-expressing CD4+ T lymphocyte population or to restore the depleted naive population in chronically HIV-infected individuals with active pulmonary tuberculosis

AIDS Research and Human Retroviruses

Volumn 29, Issue 5, 2013, Pages 769-777

  Kabue, Jean Pierre ^a   De Swardt, Dalene ^a   De Beer, Corena ^a   Glashoff, Richard H ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOUTH AFRICA; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 84876951098     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0153     Document Type: Article

References (50)

1. UNAIDS. 2011. www.unaids.org/en/media/unaids/content assets/documents/ unaidspublication/2011/JC2216-World AIDSday-report-2011-en.pdf.
2. Bassett IV, Chetty S, Wang B, et al.: Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa. J Aquir Immune Defic Syndr 2012;59(1):25-30.
3. Kamps BS and Hoffman C: Natural history of HIV. In: HIV Medicine (Hoffmann C, Rockstroh JK, Kamps BS, Eds.), 15th edition, 2007, p. 25. [Online] http://hivmedicine.com/textbook/cr.htm.
4. Almeida AS, Lago PM, Boechat N, et al.: Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009;183(1): 718-731.
5. Vrisekoop N, Mandi JN, and Germain RN: Life and death as a T lymphocyte: From immune protection to HIV pathogenesis. J Biol 2009;8(10):91.
6. Di Mascio M, Sereti I, Matthews LT, et al.: Näve T-cell dynamics in human immunodeficiency virus type 1 infection: Effects of highly active antiretroviral therapy provide insights into the mechanisms of näve T-cell depletion. J Virol 2006;80(6):2665-2674. (Pubitemid 43346362)
7. Sodora DL and Silvestri G: Immune activation and AIDS pathogenesis. AIDS 2008;22(4):439-446. (Pubitemid 351317285)
8. Dalgleish AG, Beverley PC, Clapham PR, Grawford DH, Greaves MF, and Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312(5996):763-767. (Pubitemid 15195924)
9. Princen K and Schols D: HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokines Growth Factor Rev 2005;16(6):659-677. (Pubitemid 41505522)
10. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, and Salinas-Carmona MC: Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res Hum Retroviruses 2006;22(1):45-51. (Pubitemid 43201517)
11. Morris L, Cilliers T, Bredell H, Phoswa M, and Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res and Hum Retroviruses 2001;17(8):697-701. (Pubitemid 32692408)
12. Jacobs GB, Loxton AG, Laten A, Robson B, van Rensburg EJ, and Engelbrecht S: Emergence and diversity of diversity of different HIV-1 subtypes in South Africa, 2000-2001. J Med Virol 2009;81(11):1852-1859.
13. Widdrington J, Payne B, Medhi M, Valappil M, and Schmid ML: The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011;62(1):87-92.
14. Landay Al, Betterndorf D, Chan E, et al.: Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. AIDS Res Hum Retroviruses 2002;18(2):95-102. (Pubitemid 34161228)
15. Hontelez JA, de Vlas SJ, Tauser F, et al.: The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PloS One 2011;6(7):e21919.
16. Brito A, Almeida A, Gonsalez CR, et al.: Successful HAART is associated with high b-chemokine levels in chronic HIV type 1-infected patients. AIDS Res Hum Retroviruses 2007;23(7):906-912. (Pubitemid 47267499)
17. Lang CG, Lederman MM, Madero JS, et al.: Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. J Acquir Immune Defic Syndr 2002;30(1):33-40. (Pubitemid 34506685)
18. Marques R, Williams A, Eksmond U, et al.: Generalized immune activation as a direct result of activated CD4+ T cell killing. J Biol 2009;8(10):93.
19. Aiuti F and Mezzaroma I: Failure to reconstitute CD4 + Tcells despite suppression of HIV replication under HAART. AIDS Rev 2006;8(2):88-97. (Pubitemid 44043557)
20. Massanella M, Negredo E, Perez-Alvarez N, et al.: CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 2010;24(7):959-968.
21. Bentwich Z, Maartens G, Torten D, Lal AA, and Lal RB: Concurrent infections and HIV pathogenesis. AIDS 2000; 14(14):2071-2081.
22. Morris L, Desmond J M, Bredell H, et al.: Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis in South Africa patients. J Infect Dis 2003;187(12):1967-1971. (Pubitemid 36724497)
23. Corbeau P and Reynes J: Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood 2011;117(21):5582-5590.
24. Moreno S, Hernandez B, and Dronda F: Antiretroviral therapy in AIDS patients with tuberculosis. AIDS Rev 2006;8(3):115-124. (Pubitemid 44614029)
25. Boyum A: Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968;21(Suppl 97):7.
26. Yao J, Liu Z, Ko LS, Pan G, and Jiang Y: Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods 2005;129(1):40-46. (Pubitemid 41224770)
27. Juffermans NP, Speelman P, Verbon A, et al.: Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4 ( + ) T cells. Clin Infect Dis 2001;32(4):650-652. (Pubitemid 32565010)
28. Wolday D, Tegbaru B, Kassu A, et al.: Expression of chemokine receptors CCR5 and CXCR4 on CD4+ T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J Acquir Immune Defic Syndr 2005;39(3):265-271. (Pubitemid 40923205)
29. Shalekoff S, Pendle S, Johnson D, Martin DJ, and Tiemessen CT: Distribution of the human immunodeficiency virus coreceptors CXCR4 and CCR5 on leukocytes of persons with human immunodeficiency virus type 1 infection and pulmonary tuberculosis: Implications for pathogenesis. J Clin Immunol 2001;21(6):390-401. (Pubitemid 34017073)
30. Hanna LE, Bose JC, Nayak K, Subramanyam S, and Swaminathan S: Influence of active tuberculosis on chemokine and chemokine receptor expression in HIV-infected persons. AIDS Res Hum Retroviruses 2005;21(12):997-1002. (Pubitemid 43069182)
31. Murphy K, Travers P, and Walport M: T cell-mediated Immunity. In: Janeway's Immunobiology (Taylor & Francis Group, LLC, Eds.), 7th ed. Garland Science, New York, 2008, pp. 323-377.
32. Almeida AS, Lago PM, Boechat N, et al.: Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009;183(1):718-731.
33. Geldmacher C, Ngwenyama N, Schuetz A, et al.: Preferential infection and depletion of Mycobacterium tuberculosisspecific CD4 T cells after HIV-1 infection. J Exp Med 2010; 207(13):2869-2881.
34. OstrowskiMA, Justement SJ, Catanzaro A, et al.: Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998;161(6):3195-3201. (Pubitemid 28425749)
35. Douek DC, Betts MR, Little SJ, et al.: Evidence of increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001;167(11):6663-6668. (Pubitemid 33081605)
36. Smith KY, Kumar S, Pulvirenti JJ, Gianesin M, Kessler HA, and Landay A: CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2002;30(4):458-460. (Pubitemid 34857322)
37. Zhang ZN, Shang H, Jiang YJ, et al.: Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients. Chin Med J (Engl) 2006;119(23):1966-1971. (Pubitemid 46592053)
38. Funderburg N, Kalinowska M, Eason J, et al.: Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 2010;5(10):e13188.
39. Briz V, Poveda E, Lopez E, Gonzalez Mdel M, Soviano V, and Benito JM: Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. AIDS 2008;22(11):1371-1374.
40. Benito JM, Lopez M, Lozano M, et al.: Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4 + T cells under successful highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005;38(4):373-381. (Pubitemid 40381546)
41. Morhi H, Perelson AS, Tung K, et al.: Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194(9):1277-1287. (Pubitemid 33055046)
42. Cassol E, Malfeld S, Mashasha P, et al.: Persistent microbial translocation and immune activation in HIV-1 infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010;202(5):723-733.
43. Dandekar S: Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep 2007;4(1):10-15. (Pubitemid 46555246)
44. Nakanjako D, Ssewanyana I, Mayania-Kizza H, et al.: High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011;11:43.
45. Appay V and Sauce D: Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol 2008;214(2):231-241. (Pubitemid 351160160)
46. Chakrabarti LA: The paradox of simian immunodeficiency virus infection in sooty mangabeys: Active viral replication without disease progression. Front Biosci 2004; 9:521-539. (Pubitemid 39043732)
47. Lori F: Treating HIV/AIDS by reducing immune system activation: The paradox of immune deficiency and immune hyperactivation. Curr Opin HIV AIDS 2008;3(2):99-103. (Pubitemid 351322820)
48. Guihot A, Bourgarit A, Carcelain G, and Autran B: Immune reconstitution after decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol 2011;32(3):131-137.
49. Anthony KB, Yoder C, Metcall JA, et al.: Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003;33(2):125-133. (Pubitemid 36793144)
50. Khoury G, Rajasuriar R, Cameron PU, and Lewin SR: The role of näve T-cells in HIV-1 pathogenesis: An emerging key player. Clin Immunol 2011;141(3):253-267.